Allergy, Immunology, and ENT

Latest News

ARS launches program to provide free neffy in eligible K-12 schools | Image Credit: © JoxyAimages - © JoxyAimages - stock.adobe.com.
ARS launches program to provide free neffy in eligible K-12 schools

January 22nd 2025

Eligible schools have the opportunity to receive 2 cartons of epinephrine nasal spray for use in emergency situations to treat type I allergic reactions, including anaphylaxis.

PDUFA date set for neffy 1 mg for children who weigh 33 lbs or more | Image Credit: © Postmodern Studio - © Postmodern Studio - stock.adobe.com.
PDUFA date set for neffy 1 mg for children who weigh 33 lbs or more

January 13th 2025

New data: Viaskin Peanut patch improves treatment benefit through 36 months | Image Credit: © andersphoto - © andersphoto - stock.adobe.com.
New data: Viaskin Peanut patch improves treatment benefit through 36 months

January 9th 2025

2024’s critical needle-free approvals for pediatric anaphylaxis, influenza
2024’s critical needle-free approvals for pediatric anaphylaxis, influenza

December 26th 2024

Contemporary Pediatrics’ top 3 FDA approvals of 2024
Contemporary Pediatrics’ top 3 FDA approvals of 2024

December 18th 2024

More News


Site Logo

Wheeze in Preschool Children:

April 1st 2007

Severe disability and even death can result from the inappropriate diagnosis and treatment of a young child's wheezing, which is heterogeneous in its origins and expression. Consequently, a differential diagnosis is necessary to determine the cause and to develop an effective management strategy. Viral-induced wheeze, especially from respiratory syncytial virus (RSV), manifests as a bronchiolitis. Recent reports show that the cysteinyl leukotrienes are an important mediator of the airway effects of RSV infection and that leukotriene receptor antagonists reduce postrespiratory syncytial virus lung symptoms. Exercise-induced bronchoconstriction manifests as wheezing and can be treated or pretreated short-term with inhaled bronchodilators or cromolyn: long-term therapy includes inhaled corticosteroids and leukotriene receptor antagonists. Allergic rhinitis-associated wheeze may be the result of acute exposure to an allergen or simply from nasal dysfunction. Control of allergic rhinitis with intranasal steroids, antihistamines, or leukotriene receptor antagonists could relieve the wheezing. Asthma-associated wheeze requires long-term use of 1 or more daily controller medications. The primary goal is to navigate the child safely through the first episode of wheezing, consider the causes of the wheeze, and then evaluate the need for further therapy. All apparent causes of wheeze should be treated with the idea that if the apparent cause turns out not to be the actual cause, treatment can be safely discontinued.

© 2025 MJH Life Sciences

All rights reserved.